Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|December 17, 2008
Improving decision-making in early breast cancer: who to treat and how?Antonio Llombart-Cussac
Cancer|April 4, 2023
Top advances of the year: Breast cancerCristina Saavedra, María Gion, Javier Cortés, et al.
Pathogens (Basel, Switzerland)|September 28, 2023
A New Paradigm in the Relationship between Gut Microbiota and Breast Cancer: β-glucuronidase Enzyme Identified as Potential Therapeutic TargetM Leonor Fernández-Murga, Fernando Gil-Ortiz, Lucía Serrano-García, et al.
Expert Review of Anticancer Therapy|August 30, 2024
Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancerLaia Garrigos, Daniela Camacho, José Manuel Perez-Garcia, et al.
NPJ Breast Cancer|June 28, 2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancerGiuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, et al.
Therapeutic Advances in Medical Oncology|December 6, 2021
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospectsMaría Gion, José Manuel Pérez-García, Antonio Llombart-Cussac, et al.
Clinical Breast Cancer|January 24, 2007
Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II studyAntonio Llombart-Cussac, Maria Theodoulou, Kendrith Rowland, et al.
Plos One|August 13, 2021
Lymphopenia in hospitalized patients and its relationship with severity of illness and mortalityJuan Carlos Andreu-Ballester, Aurelio Pons-Castillo, Antonio González-Sánchez, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2020
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019Serena Di Cosimo, Andrea Malfettone, José M Pérez-García, et al.
Investigational New Drugs|September 11, 2010
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II studyKatalin Boér, István Láng, Antonio Llombart-Cussac, et al.
Pageof 13